Tumor immune microenvironment and immunotherapy

Tumor immune microenvironment and immunotherapy

Guest Editors: Zlatko Trajanoski and Noel de Miranda

Cancer treatment has been revolutionized by recent unraveling and targeting of the interaction between tumors and the host immune system. Genome Medicine is pleased to announce a special issue on ‘Tumor immune microenvironment and immunotherapy’, guest edited by Zlatko Trajanoski of Medical University of Innsbruck and Noel de Miranda of Leiden University Medical Center. The issue captures recent insights using genomic approaches toward characterizing the immune system in the tumor microenvironment, immunotherapeutic targeting, as well as functional – and dysfunctional – anti-tumor immune responses, highlighting the clinical applications of these advances.

This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The Guest Editors declare that they have no competing interests.  Guest Editors serve an advisory role to guide the scope of the special issue and commissioned content; final editorial decisions lie with the Editor.

1. Content Type:Editorial

   Advancing cancer immunotherapy: a vision for the field

   Authors:Noel F. C. C. de Miranda and Zlatko Trajanoski

   Citation:Genome Medicine 2019 11:51

   Published on: 29 July 2019

   • ViewFull Text
    
   • ViewPDF
2. Content Type:Comment

   The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

   Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors u...

   Authors:Erich Sabio and Timothy A. Chan

   Citation:Genome Medicine 2019 11:43

   Published on: 24 July 2019

   • ViewFull Text
    
   • ViewPDF
3. Content Type:Research

   Evolving neoantigen profiles in colorectal cancers with DNA repair defects

   Neoantigens that arise as a consequence of tumor-specific mutations can be recognized by T lymphocytes leading to effective immune surveillance. In colorectal cancer (CRC) and other tumor types, a high number ...

   Authors:Giuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, Alessandro Magrì, Carlotta Cancelliere, Giorgio Corti, Carola Negrino, Vito Amodio, Monica Montone, Alice Bartolini, Ludovic Barault, Luca Novara, Claudio Isella, Enzo Medico, Andrea Bertotti, Livio Trusolino…

   Citation:Genome Medicine 2019 11:42

   Published on: 28 June 2019

   • ViewFull Text
    
   • ViewPDF
4. Content Type:Opinion

   Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system

   The expression of antigens that are recognized by self-reactive T cells is essential for immune-mediated tumor rejection by immune checkpoint blockade (ICB) therapy. Growing evidence suggests that mutation-ass...

   Authors:Claire Lhuillier, Nils-Petter Rudqvist, Olivier Elemento, Silvia C. Formenti and Sandra Demaria

   Citation:Genome Medicine 2019 11:40

   Published on: 20 June 2019

   • ViewFull Text
    
   • ViewPDF
5. Content Type:Comment

   Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach

   Personalized care of cancer patients undergoing treatment with immune checkpoint inhibitors will require approaches that can predict their susceptibility to immune-related adverse events. Understanding the rol...

   Authors:Zia Khan, Christian Hammer, Ellie Guardino, G. Scott Chandler and Matthew L. Albert

   Citation:Genome Medicine 2019 11:39

   Published on: 20 June 2019

   • ViewFull Text
    
   • ViewPDF
6. Content Type:Method

   Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

   We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples using simulated, flow cytometry...

   Authors:Francesca Finotello, Clemens Mayer, Christina Plattner, Gerhard Laschober, Dietmar Rieder, Hubert Hackl, Anne Krogsdam, Zuzana Loncova, Wilfried Posch, Doris Wilflingseder, Sieghart Sopper, Marieke Ijsselsteijn, Thomas P. Brouwer, Douglas Johnson, Yaomin Xu, Yu Wang…

   Citation:Genome Medicine 2019 11:34

   Published on: 24 May 2019

   The Correction to this article has been published in Genome Medicine 2019 11:50

   • ViewFull Text
    
   • ViewPDF
7. Content Type:Comment

   Discovery and characterization of actionable tumor antigens

   The nature of the tumor antigens that are detectable by T cells remains unclear. In melanoma, T cells were shown to react against major histocompatibility complex (MHC)-associated peptides (MAPs) that are deri...

   Authors:Grégory Ehx and Claude Perreault

   Citation:Genome Medicine 2019 11:29

   Published on: 30 April 2019

   The Research to this article has been published in Genome Medicine 2019 11:28

   • ViewFull Text
    
   • ViewPDF
8. Content Type:Research

   Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

   Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach ...

   Authors:Markus W. Löffler, Christopher Mohr, Leon Bichmann, Lena Katharina Freudenmann, Mathias Walzer, Christopher M. Schroeder, Nico Trautwein, Franz J. Hilke, Raphael S. Zinser, Lena Mühlenbruch, Daniel J. Kowalewski, Heiko Schuster, Marc Sturm, Jakob Matthes, Olaf Riess, Stefan Czemmel…

   Citation:Genome Medicine 2019 11:28

   Published on: 30 April 2019

   The Comment to this article has been published in Genome Medicine 2019 11:29

   • ViewFull Text
    
   • ViewPDF